Sargramostim is a recombinant granulocyte-macrophage colony-stimulating factor that supports the production and functional activity of selected myeloid cells. Its clinical relevance is linked to conditions involving impaired marrow recovery, neutrophil support, immune-cell mobilization, and specialized transplantation or infectious-disease protocols. Assessment of this market requires attention to approved indications, clinical evidence, treatment pathways, administration requirements, safety monitoring, and access conditions rather than product demand alone.

Clinical Pathways Are Reshaping Sargramostim Use

Sargramostim's position is being shaped by advances in supportive care, hematology, transplantation, oncology, and immunology. Treatment decisions increasingly depend on patient risk, marrow function, infection status, prior therapy, and the need to balance hematologic recovery with inflammatory or pulmonary safety considerations. Evidence development in immune-mediated and infectious conditions may broaden clinical discussion, while regulatory differences and treatment-guideline updates continue to determine where use is incorporated into routine practice.

Artificial Intelligence Strengthens Evidence and Care Coordination

Artificial intelligence can support sargramostim-related research and care by identifying eligible patients, harmonizing longitudinal laboratory data, detecting adverse-event patterns, and improving trial recruitment. Predictive models may help clinicians evaluate marrow-recovery trajectories and prioritize monitoring, but their usefulness depends on representative datasets, transparent validation, and integration with clinical workflows. AI should complement-not replace-physician judgment, pharmacovigilance, and regulatory review, particularly where treatment decisions involve complex immune and infectious risks.

Regional Differences Reflect Regulation, Infrastructure, and Clinical Practice

North America is characterized by comparatively extensive specialist infrastructure, structured reimbursement processes, and active evidence generation. Europe's landscape is influenced by national health-system decisions, European regulatory coordination, and variation in guideline implementation. Asia-Pacific combines advanced transplant and oncology centers with substantial differences in access, manufacturing, and diagnostic capacity. Latin America faces uneven specialist coverage and procurement conditions. Middle East systems vary between highly developed referral networks and capacity constraints, while Africa's use is most sensitive to laboratory access, infection-management capability, supply continuity, and affordability. Across all regions, appropriate patient selection and post-administration monitoring remain central.

Cross-Group Priorities Differ Across ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN markets require approaches that account for diverse regulatory systems, health-service capacity, and procurement models. BRICS members combine large and varied patient populations with differing domestic manufacturing, reimbursement, and specialist-care capabilities. The European Union emphasizes coordinated regulatory standards alongside national assessment and reimbursement decisions. G7 countries generally have mature clinical infrastructure and stronger evidence-generation networks, but still face budget and pathway-integration considerations. GCC systems often depend on centralized procurement and advanced referral centers. NATO members span diverse health systems, making harmonized preparedness, supply resilience, and clinical interoperability relevant to specialist medicines.

Country-Level Conditions Shape Adoption and Patient Access

Australia and Canada rely on specialized healthcare networks and formal assessment processes. Brazil and Mexico face regional variation in specialist access, procurement, and public-sector coverage. China and India combine expanding advanced-care capacity with substantial geographic and institutional differences. Japan and South Korea have sophisticated clinical systems supported by structured regulatory environments. France, Germany, Italy, Spain, and the United Kingdom reflect distinct reimbursement, hospital-procurement, and guideline pathways within Europe. Russia's operating environment is influenced by local regulatory, supply, and healthcare-system conditions. In the United States, specialist prescribing, payer requirements, hospital protocols, and ongoing clinical evidence strongly influence utilization.

Priorities for Leaders: Evidence, Access, Safety, and Resilience

Industry leaders should prioritize indication-specific evidence that clarifies clinical benefit, patient selection, dosing, and safety monitoring. Partnerships with transplant, oncology, infectious-disease, and immunology centers can improve real-world evidence quality and implementation. Access strategies should address reimbursement documentation, hospital formulary processes, cold-chain or handling requirements where applicable, and continuity of supply. Organizations should also establish robust pharmacovigilance, transparent AI governance, region-specific medical education, and resilient manufacturing and distribution arrangements. Engagement with clinicians, regulators, payers, and patient communities can help align product positioning with verified clinical needs.

Methodology: Evidence-Based Review of Clinical and Market-Access Drivers

This executive summary uses the supplied market topic-sargramostim-as the scope and organizes findings around clinical use, evidence development, regulation, healthcare infrastructure, access, and operational requirements. Insights are framed qualitatively and avoid market estimates, market sizing, market shares, forecasts, and unsupported numerical claims. Regional, group, and country observations synthesize established differences in healthcare-system organization and specialist-care capacity; detailed decisions should be validated against current regulatory documents, treatment guidelines, reimbursement policies, peer-reviewed studies, and local procurement conditions.

Conclusion: Disciplined Evidence Development Will Define Sargramostim's Role

Sargramostim's future clinical relevance depends on the strength and applicability of evidence across hematology, transplantation, oncology, immunology, and other evaluated care settings. Regional and country differences mean that regulatory approval, specialist expertise, reimbursement, monitoring capacity, and supply reliability must be considered together. Leaders that combine rigorous evidence generation with responsible AI use, patient-safety systems, equitable access planning, and operational resilience will be better positioned to support appropriate adoption without overstating clinical or commercial conclusions.

Product Code: MRR-961F26FD8015

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Sargramostim Market, by Dose Form

7.1. Introduction
7.2. Prefilled Syringe
7.3. Single-Dose Vial

8. Sargramostim Market, by Route Of Administration

8.1. Introduction
8.2. Intravenous
8.3. Subcutaneous

9. Sargramostim Market, by Mode Of Therapy

9.1. Introduction
9.2. Combination Therapy
9.3. Monotherapy

10. Sargramostim Market, by Indication

10.1. Introduction
10.2. Chemotherapy-Induced Neutropenia
10.3. Infection Prophylaxis
10.4. Stem Cell Transplant Support

11. Sargramostim Market, by Distribution Channel

11.1. Introduction
11.2. Hospital Pharmacy
- 11.2.1. Inpatient Pharmacy
- 11.2.2. Outpatient Pharmacy
11.3. Retail Pharmacy

12. Sargramostim Market, by End User

12.1. Introduction
12.2. Home Care
12.3. Hospital
- 12.3.1. Academic Hospital
- 12.3.2. Community Hospital
12.4. Specialty Clinic

13. Sargramostim Market, by Patient Age Group

13.1. Introduction
13.2. Adult
13.3. Pediatric

14. Sargramostim Market, by Region

14.1. Introduction
14.2. Asia-Pacific
14.3. North America
14.4. Latin America
14.5. Europe
14.6. Middle East
14.7. Africa

15. Sargramostim Market, by Group

15.1. Introduction
15.2. ASEAN
15.3. GCC
15.4. European Union
15.5. BRICS
15.6. G7
15.7. NATO

16. Sargramostim Market, by Country

16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. United Kingdom
16.7. Germany
16.8. France
16.9. Russia
16.10. Italy
16.11. Spain
16.12. China
16.13. India
16.14. Japan
16.15. Australia
16.16. South Korea

17. Competitive Landscape

17.1. Market Share Analysis, 2025
17.2. Market Concentration Analysis, 2025
- 17.2.1. Concentration Ratio (CR)
- 17.2.2. Herfindahl Hirschman Index (HHI)
17.3. Recent Developments & Impact Analysis, 2025
17.4. Product Portfolio Analysis, 2025
17.5. Benchmarking Analysis, 2025

18. Company Profiles

18.1. Amgen Inc.
18.2. Biocon Ltd.
18.3. Cadila Healthcare Ltd.
18.4. Celltrion, Inc.
18.5. Dr. Reddy's Laboratories Ltd.
18.6. Fresenius Kabi AG
18.7. Intas Pharmaceuticals Ltd.
18.8. Partner Therapeutics, Inc.
18.9. Sandoz International GmbH
18.10. Teva Pharmaceutical Industries Ltd.

19. Key Experts

Product Code: MRR-961F26FD8015

LIST OF FIGURES

FIGURE 1. Global Sargramostim Market, Years Considered for the Study
FIGURE 2. Global Sargramostim Market, Research Design
FIGURE 3. Global Sargramostim Market, Research Framework
FIGURE 4. Global Sargramostim Market, Data Triangulation
FIGURE 5. Global Sargramostim Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Sargramostim Market Size, by Dose Form, 2025 vs 2032 (%)
FIGURE 7. Global Sargramostim Market Size, by Dose Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Sargramostim Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Sargramostim Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Sargramostim Market Size, by Mode Of Therapy, 2025 vs 2032 (%)
FIGURE 11. Global Sargramostim Market Size, by Mode Of Therapy, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Sargramostim Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 13. Global Sargramostim Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Sargramostim Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Sargramostim Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Sargramostim Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global Sargramostim Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Sargramostim Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 19. Global Sargramostim Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Sargramostim Market Size, by Region, 2025 vs 2032 (%)
FIGURE 21. Global Sargramostim Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global Sargramostim Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Sargramostim Market Size, by Country, 2025 vs 2032 (%)
FIGURE 24. Global Sargramostim Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 25. Global Sargramostim Market Share, by Key Player, 2025

LIST OF TABLES

TABLE 1. Global Sargramostim Market Segmentation & Coverage
TABLE 2. Global Sargramostim Market Size, 2017-2032 (USD Million)
TABLE 3. Global Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 4. Global Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Single-Dose Vial Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Single-Dose Vial Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Single-Dose Vial Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 11. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 18. Global Combination Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 19. Global Combination Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 20. Global Combination Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 21. Global Monotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global Monotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global Monotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 25. Global Chemotherapy-Induced Neutropenia Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Chemotherapy-Induced Neutropenia Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Chemotherapy-Induced Neutropenia Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Infection Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Infection Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Infection Prophylaxis Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Stem Cell Transplant Support Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Stem Cell Transplant Support Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Stem Cell Transplant Support Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 35. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Inpatient Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Inpatient Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Inpatient Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Outpatient Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Outpatient Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Outpatient Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 48. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Academic Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Academic Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Academic Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Community Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Community Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Community Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Specialty Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Specialty Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Specialty Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 64. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Sargramostim Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific Sargramostim Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 78. Asia-Pacific Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 79. Asia-Pacific Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 80. Asia-Pacific Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 81. North America Sargramostim Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. North America Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 83. North America Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 84. North America Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 85. North America Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 86. North America Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 87. North America Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 88. North America Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 89. North America Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 90. North America Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 91. Latin America Sargramostim Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Latin America Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 93. Latin America Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 94. Latin America Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 95. Latin America Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 96. Latin America Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 97. Latin America Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 98. Latin America Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 99. Latin America Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 100. Latin America Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 101. Europe Sargramostim Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Europe Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 103. Europe Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 104. Europe Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 105. Europe Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 106. Europe Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 107. Europe Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 108. Europe Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 109. Europe Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 110. Europe Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 111. Middle East Sargramostim Market Size, by Region, 2017-2032 (USD Million)
TABLE 112. Middle East Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 113. Middle East Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 114. Middle East Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 115. Middle East Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 116. Middle East Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 117. Middle East Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 118. Middle East Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 119. Middle East Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 120. Middle East Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 121. Africa Sargramostim Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. Africa Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 123. Africa Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 124. Africa Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 125. Africa Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 126. Africa Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 127. Africa Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 128. Africa Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 129. Africa Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 130. Africa Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 131. Global Sargramostim Market Size, by Group, 2017-2032 (USD Million)
TABLE 132. ASEAN Sargramostim Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. ASEAN Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 134. ASEAN Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 135. ASEAN Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 136. ASEAN Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 137. ASEAN Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 138. ASEAN Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 139. ASEAN Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 140. ASEAN Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 141. ASEAN Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 142. GCC Sargramostim Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. GCC Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 144. GCC Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 145. GCC Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 146. GCC Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 147. GCC Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 148. GCC Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 149. GCC Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 150. GCC Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 151. GCC Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 152. European Union Sargramostim Market Size, by Group, 2017-2032 (USD Million)
TABLE 153. European Union Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 154. European Union Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 155. European Union Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 156. European Union Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 157. European Union Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 158. European Union Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 159. European Union Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 160. European Union Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 161. European Union Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 162. BRICS Sargramostim Market Size, by Group, 2017-2032 (USD Million)
TABLE 163. BRICS Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 164. BRICS Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 165. BRICS Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 166. BRICS Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 167. BRICS Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 168. BRICS Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 169. BRICS Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 170. BRICS Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 171. BRICS Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 172. G7 Sargramostim Market Size, by Group, 2017-2032 (USD Million)
TABLE 173. G7 Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 174. G7 Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 175. G7 Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 176. G7 Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 177. G7 Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 178. G7 Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 179. G7 Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 180. G7 Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 181. G7 Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 182. NATO Sargramostim Market Size, by Group, 2017-2032 (USD Million)
TABLE 183. NATO Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 184. NATO Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 185. NATO Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 186. NATO Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 187. NATO Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 188. NATO Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 189. NATO Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 190. NATO Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 191. NATO Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 192. Global Sargramostim Market Size, by Country, 2017-2032 (USD Million)
TABLE 193. United States Sargramostim Market Size, 2017-2032 (USD Million)
TABLE 194. United States Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 195. United States Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 196. United States Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 197. United States Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 198. United States Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 199. United States Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 200. United States Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 201. United States Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 202. United States Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 203. Canada Sargramostim Market Size, 2017-2032 (USD Million)
TABLE 204. Canada Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 205. Canada Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 206. Canada Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 207. Canada Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 208. Canada Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 209. Canada Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 210. Canada Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 211. Canada Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 212. Canada Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 213. Mexico Sargramostim Market Size, 2017-2032 (USD Million)
TABLE 214. Mexico Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 215. Mexico Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 216. Mexico Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 217. Mexico Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 218. Mexico Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 219. Mexico Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 220. Mexico Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 221. Mexico Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 222. Mexico Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 223. Brazil Sargramostim Market Size, 2017-2032 (USD Million)
TABLE 224. Brazil Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 225. Brazil Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 226. Brazil Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 227. Brazil Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 228. Brazil Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 229. Brazil Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 230. Brazil Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 231. Brazil Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 232. Brazil Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 233. United Kingdom Sargramostim Market Size, 2017-2032 (USD Million)
TABLE 234. United Kingdom Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 235. United Kingdom Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 236. United Kingdom Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 237. United Kingdom Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 238. United Kingdom Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 239. United Kingdom Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 240. United Kingdom Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 241. United Kingdom Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 242. United Kingdom Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 243. Germany Sargramostim Market Size, 2017-2032 (USD Million)
TABLE 244. Germany Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 245. Germany Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 246. Germany Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 247. Germany Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 248. Germany Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 249. Germany Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 250. Germany Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 251. Germany Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 252. Germany Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 253. France Sargramostim Market Size, 2017-2032 (USD Million)
TABLE 254. France Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 255. France Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 256. France Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 257. France Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 258. France Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 259. France Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 260. France Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 261. France Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 262. France Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 263. Russia Sargramostim Market Size, 2017-2032 (USD Million)
TABLE 264. Russia Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 265. Russia Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 266. Russia Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 267. Russia Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 268. Russia Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 269. Russia Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 270. Russia Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 271. Russia Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 272. Russia Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 273. Italy Sargramostim Market Size, 2017-2032 (USD Million)
TABLE 274. Italy Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 275. Italy Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 276. Italy Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 277. Italy Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 278. Italy Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 279. Italy Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 280. Italy Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 281. Italy Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 282. Italy Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 283. Spain Sargramostim Market Size, 2017-2032 (USD Million)
TABLE 284. Spain Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 285. Spain Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 286. Spain Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 287. Spain Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 288. Spain Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 289. Spain Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 290. Spain Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 291. Spain Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 292. Spain Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 293. China Sargramostim Market Size, 2017-2032 (USD Million)
TABLE 294. China Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 295. China Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 296. China Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 297. China Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 298. China Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 299. China Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 300. China Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 301. China Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 302. China Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 303. India Sargramostim Market Size, 2017-2032 (USD Million)
TABLE 304. India Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 305. India Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 306. India Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 307. India Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 308. India Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 309. India Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 310. India Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 311. India Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 312. India Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 313. Japan Sargramostim Market Size, 2017-2032 (USD Million)
TABLE 314. Japan Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 315. Japan Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 316. Japan Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 317. Japan Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 318. Japan Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 319. Japan Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 320. Japan Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 321. Japan Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 322. Japan Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 323. Australia Sargramostim Market Size, 2017-2032 (USD Million)
TABLE 324. Australia Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 325. Australia Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 326. Australia Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 327. Australia Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 328. Australia Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 329. Australia Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 330. Australia Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 331. Australia Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 332. Australia Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 333. South Korea Sargramostim Market Size, 2017-2032 (USD Million)
TABLE 334. South Korea Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
TABLE 335. South Korea Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 336. South Korea Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
TABLE 337. South Korea Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
TABLE 338. South Korea Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 339. South Korea Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 340. South Korea Sargramostim Market Size, by End User, 2017-2032 (USD Million)
TABLE 341. South Korea Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 342. South Korea Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 343. Global Sargramostim Market Share, by Key Player, 2025
TABLE 344. Global Sargramostim Market, Key Experts

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ

SELECT AN OPTION